BRIDGEWATER, N.J., Nov. 15, 2013 /PRNewswire/ -- CorMedix Inc. (NYSE MKT: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardio-renal and infectious disease, today announced that the Company will report financial results for the third quarter ended September 30, 2013 after the close of trading on Tuesday, November 19, 2013.
CorMedix has filed form 12b-25 with the U.S. Securities and Exchange Commission (the "SEC"), and as a result, the deadline for the Company to file its quarterly report on Form 10-Q with the SEC has been extended to November 19, 2013.
CorMedix management will hold a conference call on Wednesday, November 20, 2013, at 9a.m. EST to discuss the results and provide an update on recent business developments. To access the call, please dial 1-866-866-1333 in the United States, and 1-404-260-1421 internationally. A live webcast of the conference call will also be available on the investor relations page of the Company's website at www.cormedix.com.
For those unable to participate, a telephonic replay of the call will be available until December 4, 2013. The replay dial-in numbers are 1-866-430-1300 for domestic callers and 1-404-260-1414 for international callers. Please use event PIN 4804300 and confirmation number 201311142204363 to access the replay. Additionally, an archived webcast of the event will be available on the CorMedix website for 90 days.
CorMedix Inc. is a development-stage pharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. CorMedix's most advanced product candidate is Neutrolin®, catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Please see the company's website at www.cormedix.com for additional information.
|SOURCE CorMedix Inc.|
Copyright©2012 PR Newswire.
All rights reserved